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Abstract
Biological rhythms have always been considered to be disrupted in depression, with the predominant theory being
that of hyperarousal. However, recent data suggest that it might be more appropriate to suggest that depressed
patients are incapable of achieving and maintaining the particular level of internal homeostasis which permits
them to function smoothly, to lower the level of arousal during sleep sufficiently so that quality of sleep is good,
and to increase this level enough during the day so the person can function properly. Therefore, the transition
from one state to another is somewhat problematic, delayed, incomplete and desynchronised. Thus, agents with a
‘rhythm stabilising’ effect could be beneficial in the treatment of mood disorders. Such an agent should have a
beneficial effect on restoring and stabilising the rhythm of a physiological function while not pushing it towards a
specific pole, or inducing the opposite pole; it should also allow response to internal and environmental stimuli
and zeitgebers, and restore synchronisation of the various body rhythms while not inducing or worsening desyn-
chronisation. Agomelatine could represent the first of a new class of ‘rhythm stabilising antidepressants’, but further
research is necessary to support this theory.
Introduction
Biological rhythms have always been considered to be
disrupted in depression [1]. In the seminal paper by
Akiskal and McKinney [2] it has been concluded that
depression is related to hyperarousal, because depressive
patients have lower threshold for awakening, rapid eye
movement (REM) sleep disorders and loss of delta
waves related sleep, which is the deepest stage of non-
REM sleep. By ‘hyperarousal’, it is denoted that
depressed patients manifest both higher reactivity to
environmental stimuli and sympathetic nervous system
(SNS) hyperactivity. According to this approach, sleep
disorders are considered in the frame of higher vigilance
[3]. Some authors reject this theory and suggest that
only somatisation can involve altered central nervous
system (CNS) processing (hyperarousal) of somatic sti-
muli [4]. Theoretically, a disturbance of biological
rhythms could be a core feature in the etiopathogenesis
of depression [5-7].
However, from a clinical point of view depression is
not a uniform clinical entity. Even for unipolar depres-
sion it is not known whether it is a single disorder or a
spectrum of different disorders with overlapping clinical
manifestations. Clinically, depressed patients do not
manifest sleep disorders alone (difficulty in initiating or
sustaining sleep or low sleep quality). The same patients,
when awake, manifest concentration difficulties, reduced
psychomotor activity, fatigue, somnolence and so on,
and these symptoms could be independent from the
sleep they experienced the previous night (that is, they
are not always consequences of poor sleeping).
Melancholic patients in particular typically manifest
sleep disorders during the night (insomnia) and fatigue,
concentration difficulties and anhaedonia with a lack of
prominent anxiety during the daytime. These could be
suggestive of a reduction of the arousal level variation
span. According to this theory, the arousal level is not
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normal sleep, while during the daytime it is not suffi-
ciently increased so as to lead to normal functioning.
On the contrary, atypical patients manifest hypersomnia,
higher levels of anxiety and personality disorders as well
as increased reactivity towards the environment. These
are suggestive of an increased variation range of the
arousal level, which during the night could be too low,
leading to a prolonged but low quality sleep, while dur-
ing the daytime the level may be too high, thus leading
to anxiety and hyperactivity.
So although the hyperarousal theory for depression is
generally accepted and mainly derives from the consis-
tent finding of a lower threshold for awakening, rapid
eye movement (REM) sleep disturbances and loss of
delta-activity-related sleep, the data in the literature
s u g g e s tt h a tt h eg e n e r a l i s e dt e r m‘hyperarousal’ could
be misleading in the case of depression. Depression is
characterised by a disruption of the span of variation
of the activity of several brain region functions and a
desynchronisation of the sequence of activation/deacti-
vation of various neural circuits, as a response to
external stimuli or to states of the organism. This
results in the compromise of many functions, and may
constitute the cause for the formation of symptomatol-
ogy. This could be true both at the level of specific
brain regions and at the level of coordination between
different brain structures, and it can be state or syn-
drome dependent [8-10].
Additionally, anxiety is generally considered to be a
sign of an increased level of alertness, however it might
be wrong to identify these two concepts as related.
Anxiety and nervousness are the consequences of poor
sleep or prolonged insomnia even in normal subjects,
but are not present under standard and normal condi-
tions; at those hours of the day the circadian cycle
indices have the greatest difference from the respective
values during sleep. That is, anxiety is not related to
those periods of the day when alertness is at its highest.
Taking all the above into consideration, it might be
more appropriate to suggest that depressed patients are
incapable of achieving and maintaining the particular
level of internal homeostasis that permits the person to
function smoothly, to lower enough the level of arousal
during sleep so that quality of sleep is good, and to
increase this level enough during the day so that the
person can function properly. The same seems to hold
true not only for circadian but also for ultradian varia-
tions. Therefore the transition from one state to another
is somewhat problematic, delayed, incomplete and
desynchronised. This is in accord with the suggestion of
Bruder et al. [11] that a fused arousal/attentional system
involving temporoparietal and possibly frontal regions is
dysfunctional in depression, and the suggestion of
Shagas et al. [12,13] that depressed patients may be
underactivated at rest but over-reactive after stimulation.
This disregulation of rhythms could be either a core
etiopathogenetic factor or a severe manifestation of
depression, and therefore needs specific evaluation and
treatment [14,15]. Treating with a hypnotic or sedative
is not appropriate; on the contrary, there are reports in
the literature that such a treatment might worsen the
long term outcome of these patients, but this could be
mainly because of the addiction patients develop.
Thus agents with a ‘rhythm stabilising’ effect could be
beneficial in the treatment of mood disorders. The term
‘rhythm stabiliser’ could be defined in a similar way to
how the term ‘mood stabilizer’ is perceived today
[16-18], that is ‘a compound that has been shown to be
efficacious in recurrence prevention of manic and
depressive symptoms, but not necessarily in the treat-
ment of the acute manic or depressive phase, although
it would be an advantage if it were’ [16]. A similar more
realistic definition suggests that the term ‘mood stabili-
ser’ describes an agent that ideally ‘would prevent
relapse to either pole of the illness’ [16] without causing
a negative effect on other phases of the illness [19]. Fol-
lowing this path, the criteria that could define a ‘rhythm
stabiliser’ can be specific and operational but of course
only further research can provide answers.
Such an agent should have a beneficial effect on the
rhythm of a physiological function (restoring and stabi-
lising it) and not pushing it towards a specific pole (as,
for example, hypnotics do). This restoration should
include the whole pattern of the rhythm of the function
under consideration (period/frequency and amplitude)
and its relationship to other body functions. Some
rhythms have a very complex pattern and periodicity
and the restoration should be as close to normality as
possible, but at the same time the fixation to normality
should not be too rigid and should allow response to
both internal and environmental stimuli and zeitgebers
and space for adaptation to change if needed. The ques-
tion of whether an effect on a single rhythm would be
sufficient to warrant the characterisation of a ‘rhythm
stabilizer’ or a broader effect on multiple physiological
functions is necessary, cannot be addressed sufficiently
today. A broad definition will include even compounds
acting on a single function. The most important prop-
erty of a ‘stabiliser’ would be to not induce the opposite
pole in the physiological function it is supposed to
restore or in any other function, and further, to restore
synchronisation of the various body rhythms and not
induce or worsen dysynchronisation.
A final question concerns the source of data suggest-
ing the agent has ‘stabilised’ the rhythm. They could
come from direct clinical observations and interviews
with the subject, or from laboratory investigation. This
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might be at least some functions (for example, sleep,
daily energy and fatigue) that can be accessed through
clinical observation and interview (at least to a fair
degree), however the vast majority of functions would
need sophisticated laboratory assessment, which is not
available in most clinical settings. An ‘either/or’ phrase
might be the best compromise for the time being.
A summary of proposed criteria for further study con-
cerning the definition and the properties a ‘rhythm sta-
biliser’ should fulfil is presented in Table 1.
In the frame of the above, the development of agome-
latine could represent a new approach to the treatment
of depression, since it could be the first compound that
fulfils the criteria for a ‘rhythm stabilising antidepres-
sant’. Unlike other antidepressants, agomelatine has a
novel neurochemical mechanism of action since it is an
MT1 and MT2 melatonergic receptor agonist and an
antagonist at the 5-HT2C receptor. By interacting with
these receptor subtypes it causes the restoration of cir-
cadian rhythms [20]. Randomised controlled trials sug-
gest that it leads to a global and rapid amelioration of
depression by relieving the core symptoms of depres-
sion, including depressed mood, anxiety symptoms, and
those that frequently remain untouched by other antide-
pressants (for example, sleep/wake disturbances), while
important functions such as sexual function remain
intact. At the same time, remission rates are reported to
be satisfactorily high [21].
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